AKI Therapeutics A/S: Financial statements 2017
CVR: 37509736
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -4,000 and a net result of DKK -13,401 compared with DKK -7,564 the year before. Equity in the 2017 report amounted to DKK 29,035. The solvency ratio was 85.3%.
- Gross Profit
- DKK -4,000
- Profit/Loss
- DKK -13,401
- Equity
- DKK 29,035
- Total Assets
- DKK 34,037
Official annual report
Keep an eye on AKI Therapeutics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
AKI Therapeutics A/S has published its interim report for the period March 1, 2016 to December 31, 2016.
About AKI Therapeutics A/S
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.